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On October 1996, a 14-year-old girl was admitted to the hospital because cutaneous lesions, asthenia, and arthralgias. On
examination, there was nonscarring hair thinning with a widened part over the frontal hairline, polymorphic papulosquamous
rash on her face, neck, arms, and trunk, and livedo reticularis in her legs. Multiple aphtous ulcers were present on the buccal
and nasal mucosa. There was polyarthritis involving the wrist, metacarpophalangeal joints, proximal interphalangeal joints,
and metatarsophalangeal joints of both hands and feet. Skin biopsy of the face was compatible with subacute cutaneous lupus
erythematosus. She started on prednisone 60mg/d without improvement, and later hdroxhchloroquine (HCQ) 6mg/kg/d was
added for one year. Cutaneous lesions were almost healed, with just a hypopigmented macules left. Over the last 14 years, she has
not shown any cutaneous or systemic manifestations.
1.CaseReport
On October 1996, a 14-year-old girl was admitted to the
hospital because of cutaneous lesions, asthenia, and arthral-
gias. She had been in good health until four months earlier,
when she began to experience asthenia, decreased appetite,
photosensitivity, hair loss, erythematous papules on her face,
and diﬀuse arthralgias. On examination, the patient’s blood
pressure was 110/60mm Hg, her temperature was 36,8◦C,
her pulse rate was 68 beats/min, and her respiration rate was
16 breaths/min.
There was nonscarring hair thinning with a widened part
over the frontal hairline, polymorphic papulosquamous rash
on her face, neck, arms, and trunk, (Figures 1 and 2), and
livedo reticularis in her legs. Multiple aphtous ulcers were
present on the buccal and nasal mucosa. There was pol-
yarthritis involving the wrist, metacarpophalangeal joints,
proximal interphalangeal joints, and metatarsophalangeal
joints of both hands and feet. The rest of the physical
examination ﬁndings were normal.
A complete blood count with diﬀerential analysis, liver
function tests, chemistry panel, muscle enzymes, and urinal-
ysis was normal. A test for antinuclear antibodies (ANA) was
positive at a titer of 1:160 with a homogeneous-speckled
pattern, but the remainder of the antinuclear-antibody
screening (anti-double-stranded DNA, anti-Ro/SSA, anti-
La/SSB, and anti ENA) was negative. An antineutrophil
cytoplasmic antibody (ANCA) test, rheumatoid factor, anti-
cardiolipin antibodies Ig G and Ig M, VDRL, and HIV were
all negative. Complement levels (C3, C4, and CH50) were
within normal limits.
A chest X-ray, an electrocardiogram, an transthoracic
echocardiography, and an abdominal US were normal.
Skin biopsy of the face was compatible with subacute
cutaneous lupus erythematosus (Figure 3).
She started with prednisone 60mg/d without improve-
ment; after two months this medication was discontinued.
Later hydroxychloroquine (HCQ) 6mg/kg/d was added for
one year, then, the dose was tapered to 3mg/kg/d. The
patient had an extraordinary response to HCQ. Cutaneous
lesions were almost healed, with just a hypopigmented
macules left. Over the last 14 years, she has not shown any
cutaneous or systemic manifestations.
2. Discussion
The skin lesions seen in patients with lupus can be classiﬁed
into those that are lupus-speciﬁchistologically and those2 ISRN Dermatology
Figure 1: Photosensible malar rash with multiple, symmetric, red
to violaceous slightly scaly conﬂuent papules and plaques. Some of
the small papules became conﬂuent to form large plaques.
Figure 2: Multiple red to violaceous conﬂuent papules and plaques
on the face, trunk, arms, and abdomen.
that are lupus-nonspeciﬁc. There are three broad categories
of LE-speciﬁc skin disease: acute cutaneous LE (ACLE),
subacute cutaneous LE (SCLE), and chronic cutaneous LE
(CCLE) [1].
Subacute cutaneous lupus erythematosus is a photosen-
sitive, superﬁcial nonscarring type of cutaneous LE, with
lesions being seen most commonly on the V area, upper
back, shoulders, extensor surfaces of the arms and forearms,
and dorsum of the hands [2]. SCLE has two clinical forms:
Figure 3: Cheek biopsy showing epidermal atrophy, vacuolar
interface dermatitis (arrow) with necrotic keratinocytes in the
epidermis, and a perivascular inﬁltrate with lymphocytes and
macrophages (arrowhead).
annularSCLEandpapulosquamousSCLE[1,2].Ourpatient
presented papulosquamous lesions.
During the cutaneous outbreak, patients often have
systemic manifestations, particularly at the articular level, as
it happened with our patient.
Approximately 70% of all SCLE patients have Ro/SSA
(+) [1]. Nonspeciﬁc LE skin lesions such as vasculitis, livedo
reticularis, and alopecia are frequently seen in patients with
cutaneous LE [3].
About half of all patients with SCLE fulﬁl four or more
of the American College of Rheumatology (ACR) criteria for
systemic lupus erythematosus (SLE) but have been noted
to have a mild subset of systemic disease[2]. Our patient
has ﬁve ACR criteria for SLE classiﬁcation (malar rash,
photosensitivity, oral ulcers, arthritis, and ANA positivity).
The histologic hallmark of LE-speciﬁc skin lesions is the
vacuolar degeneration in the basal layer of the epidermis
(hydropic or liquefactive degeneration) [1].
Sunscreens are a cornerstone of therapy and they should
be applied daily to all exposed surfaces. Low-to-medium
potency topical steroids should be used to treat facial lesions
andtrunkandarmlesionswithmedium-potencyagents,and
lesions on the palms and soles should be treated with high-
potency topical glucocorticoids. Systemic corticosteroids are
partially eﬀective for SCLE lesions; however, because of
the delayed onset of action of antimalarials, there may be
indicated despite their potential severe side eﬀects, such as
avascular necrosis, hypeglycemia, or osteoporosis [4, 5].
The most useful systemic agents for treating LE-speciﬁc
skin lesions are the aminoquinoline antimalarial agents.
They have multiple sun blocking, anti-inﬂammatory and
immunosuppressive eﬀects. Antimalarials occrue in diﬀer-
ent concentrations among the various body tissues andISRN Dermatology 3
organs. The highest of all concentrations occurs in melanin-
containingcellssuchasfoundintheretinaandskin.Hydrox-
ychloroquine is the initial treatment of choice. Its onset of
action is approximately 1 month, even though its full beneﬁt
might not be seen for several months. It is typically dosed at
200 or 400mg per day and should not exceed 6.5mg/kg/d.
At these doses, it is usually well tolerated. Chloroquine is
more toxic and it is used in a 4mg/kg/d dose. Quinacrine
does not cause retinal toxicity, and thus can be used in
combination with either hydroxychloroquine or chloroquine
[6]. Approximately 75% of SCLE patients improved with
antimalarials agents, smokers are less likely to do so [5].
Other treatments include thalidomide, topical tacroli-
mus, dapsone, gold salts, oral retinoids, and oral fenitoin.
Cytotoxic immunosuppressive agents, such as azathioprine,
mycophenolate mofetil, and methotrexate are reserved for
patients with more severe disease who have failed the less
toxic forms of therapy [4].
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